<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124042</url>
  </required_header>
  <id_info>
    <org_study_id>XT-150-2-0204</org_study_id>
    <nct_id>NCT04124042</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of XT-150 in Osteoarthritis of the Knee</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xalud Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xalud Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing&#xD;
      moderate to severe pain due to osteoarthritis of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing&#xD;
      moderate to severe pain due to osteoarthritis of the knee.&#xD;
&#xD;
      Baseline confirmation of study eligibility will be completed the day before or day of study&#xD;
      drug administration.&#xD;
&#xD;
      Study drug will be administered by intra-articular (IA) injection into the joint space of the&#xD;
      knee.&#xD;
&#xD;
      Up to 270 participants will be randomly enrolled into 1 of 3 treatment groups (90&#xD;
      participants/ group). Treatment Groups:&#xD;
&#xD;
        1. Placebo (1 mL)&#xD;
&#xD;
        2. Low dose XT-150 (1 mL)&#xD;
&#xD;
        3. High dose XT-150 (1 mL)&#xD;
&#xD;
      The study will be conducted in 2 stages, A and B:&#xD;
&#xD;
      A. Placebo-controlled for 6 months&#xD;
&#xD;
      B. Continued follow up for 6 months with the option of receiving one of two doses of XT-150&#xD;
      injection to the index knee.&#xD;
&#xD;
      Final assessments will be 12 months after the first IA dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, blinded, placebo-controlled, study of pain due to OA of the knee</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score(KOOS)/Western Ontario and McMasters Arthritis Index (WOMAC)</measure>
    <time_frame>12 months</time_frame>
    <description>Responder Rates in KOOS/WOMAC scores, higher KOOS scores and lower WOMAC scores indicate improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Interference</measure>
    <time_frame>12 month</time_frame>
    <description>Response rates in all dimensions of the short-form Brief Pain Inventory and Interference, lower scores indicate improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment</measure>
    <time_frame>12 months</time_frame>
    <description>OA question, &quot;Considering all the ways the OA in your knee affects you, how are you doing today?&quot; on scale of 1-5, with 5 as worst</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose XT-150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose active, experimental treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose XT-150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose active, experimental treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XT-150</intervention_name>
    <description>plasmid DNA</description>
    <arm_group_label>High Dose XT-150</arm_group_label>
    <arm_group_label>Low Dose XT-150</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic disease due to osteoarthritis, defined as a WOMAC Pain score ≥ 8 (worst&#xD;
             possible = 20)&#xD;
&#xD;
          2. Focused Analgesia Selection Test will be used to determine whether patients can report&#xD;
             pain with sufficient consistency to enter the clinical trial&#xD;
&#xD;
          3. Males and females between 45 and 85 years of age, inclusive&#xD;
&#xD;
          4. Kellgren-Lawrence grading of 2 or 3 within the last 6 months&#xD;
&#xD;
          5. Stable analgesic regimen during the 4 weeks prior to enrollment&#xD;
&#xD;
          6. In the judgment of the Investigator, acceptable general medical condition&#xD;
&#xD;
          7. Life expectancy &gt;6 months&#xD;
&#xD;
          8. Male and female participants who are heterosexually active and not surgically sterile&#xD;
             must agree to use effective contraception, including abstinence, for the duration of&#xD;
             the study&#xD;
&#xD;
          9. Have suitable knee joint anatomy for intra-articular injection&#xD;
&#xD;
         10. Willing and able to return for the follow-up (FU) visits&#xD;
&#xD;
         11. Able to read and understand study instructions, and willing and able to comply with&#xD;
             all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity, allergy, or significant reaction to any ingredient of the study&#xD;
             drug, including double-stranded DNA, mannose, and sucrose&#xD;
&#xD;
          2. Previously received XT-150 injection(s)&#xD;
&#xD;
          3. Scheduled partial or complete knee replacement within 6 months; participant agrees not&#xD;
             to schedule a knee replacement during Stage A of the study&#xD;
&#xD;
          4. History of knee arthroplasty on the Index Knee, i.e., selected for study injection(s)&#xD;
&#xD;
          5. History of rheumatoid arthritis or other inflammatory disease&#xD;
&#xD;
          6. History of immunosuppressive therapy; systemic steroids in the last 3 months&#xD;
&#xD;
          7. Received knee injection with hyaluronic acid or stem-cells in the last 6 months&#xD;
&#xD;
          8. Knee injection of glucocorticoid in the last 3 months&#xD;
&#xD;
          9. Current treatment with systemic immunosuppressive (systemic corticosteroid therapy or&#xD;
             other strong immunosuppressant)&#xD;
&#xD;
         10. Currently receiving systemic chemotherapy or radiation therapy for malignancy&#xD;
&#xD;
         11. Clinically significant hepatic disease as indicated by clinical laboratory results ≥3&#xD;
             times the upper limit of normal for any liver function test (e.g., aspartate&#xD;
             aminotransferase, alanine aminotransferase)&#xD;
&#xD;
         12. Severe anemia (Grade 3; hemoglobin &lt;8.0 g/dL, &lt;4.9 mmol/L, &lt;80 g/L; transfusion&#xD;
             indicated), Grade 1 white cell counts (lymphocytes &lt;LLN - 800/mm3; &lt;LLN - 0.8 x 109&#xD;
             /L, neutrophils &lt;LLN - 1500/mm3; &lt;LLN - 1.5 x 109 /L), LLN=Lower Limit Normal Range&#xD;
&#xD;
         13. Positive serology for human immunodeficiency virus, hepatitis B virus, or hepatitis C&#xD;
             virus&#xD;
&#xD;
         14. Significant neuropsychiatric conditions; dementia, major depression, or altered mental&#xD;
             state that in the opinion of the Investigator will interfere with study participation&#xD;
&#xD;
         15. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical&#xD;
             treatments)&#xD;
&#xD;
         16. Current anticoagulant or anti-platelet treatment (e.g., warfarin, heparins, factor X&#xD;
             inhibitors, clopidogrel, prasugrel, ticagrelor, or dipyridamole). Low-dose (≤ 325&#xD;
             mg/day) aspirin is permitted&#xD;
&#xD;
         17. Known or suspected history of active alcohol or intravenous/oral drug abuse within 1&#xD;
             year before the screening visit&#xD;
&#xD;
         18. Use of any investigational drug or device within 3 months before enrollment or current&#xD;
             participation in a trial that included intervention with a drug or device; or&#xD;
             currently participating in an investigational drug or device study&#xD;
&#xD;
         19. Any condition that, in the opinion of the Investigator, could compromise the safety of&#xD;
             the participant, the participant's ability to communicate with the study staff, or the&#xD;
             quality of the data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen D Collins, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xalud Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurovations (Napa Pain Institute)</name>
      <address>
        <city>Napa</city>
        <state>California</state>
        <zip>94558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Source Healthcare</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Clinical Research Institute</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Adelaide in collaboration with CMAX Clinical Research Pty Ltd</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5005</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Pain</keyword>
  <keyword>Interleukin</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>plasmid DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

